Biocon has posted Q3 revenue of Rs 1,511 crore, EBIDTA of Rs 425 crore and Profit after tax of Rs 241 crore. Kiran Mazumdar Shaw, CMD Biocon said that the company witnessed exception licensing income last year on account of the Pfizer deal. Licensing income in Q3 was, therefore, sharply down from the exceptional levels recorded last fiscal which resulted in flat earnings overall, she said.
